TGFB1 and metabolic dysfunction-associated steatotic liver disease: The inhibition of the TGF-β pathway in a mouse model of NAFLD has been demonstrated to result in reduced activation of HSCs and alleviated fibrosis, with the most pronounced effect observed when IL13 is concurrently suppressed (114).